CoChat
Sign Up
Cited by 1,807Immune cells in cancerCancer Immunotherapy and BiomarkersPhagocytosis and Immune Regulation

Macrophages as tools and targets in cancer therapy

Open access
Mantovani, Alberto, Allavena, Paola, Marchesi, Federica, Garlanda, Cecilia·2022·Nature Reviews Drug Discovery
DOI 10.1038/s41573-022-00520-5PMC PMC9380983
Open this paper in CoChat — free accountOpen PDF

Abstract

Tumour-associated macrophages are an essential component of the tumour microenvironment and have a role in the orchestration of angiogenesis, extracellular matrix remodelling, cancer cell proliferation, metastasis and immunosuppression, as well as in resistance to chemotherapeutic agents and checkpoint blockade immunotherapy. Conversely, when appropriately activated, macrophages can mediate phagocytosis of cancer cells and cytotoxic tumour killing, and engage in effective bidirectional interactions with components of the innate and adaptive immune system. Therefore, they have emerged as therapeutic targets in cancer therapy. Macrophage-targeting strategies include inhibitors of cytokines and chemokines involved in the recruitment and polarization of tumour-promoting myeloid cells as well as activators of their antitumorigenic and immunostimulating functions. Early clinical trials suggest that targeting negative regulators (checkpoints) of myeloid cell function indeed has antitumor potential. Finally, given the continuous recruitment of myelomonocytic cells into tumour tissues, macrophages are candidates for cell therapy with the development of chimeric antigen receptor effector cells. Macrophage-centred therapeutic strategies have the potential to complement, and synergize with, currently available tools in the oncology armamentarium.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41573-022-00520-5

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Myeloid cells are required for antigen presentation, T cell support and effective anti-tumor responses.

    “However, myeloid cells are required for antigen presentation, T cell support and effective anti-tumor responses (15).”

    From Cholesterol efflux protein, ABCA1, supports anticancer functions of myeloid immune cells (2026) · cites this paper as [15]

    The CD40 section (page unavailable) identifies macrophages as antigen-presenting cells that can stimulate T cell-mediated immunity, and the Introduction describes their potential to activate antitumour lymphoid responses. These passages support a beneficial role for some myeloid cells, but do not establish that myeloid cells are required for antigen presentation, T cell support, or effective antitumour responses generally. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 259

  1. [1]Balkwill F Mantovani A Inflammation and cancer: back to Virchow? Lancet 2001 357 539 545 10.1016/S0140-6736(00)04046-0 11229684 · DOI · Paper page
  2. [2]Mantovani A Allavena P Sica A Balkwill F Cancer-related inflammation Nature 2008 454 436 444 10.1038/nature07205 18650914 · DOI · Paper page
  3. [3]Engblom C Pfirschke C Pittet MJ The role of myeloid cells in cancer therapies Nat. Rev. Cancer 2016 16 447 462 10.1038/nrc.2016.54 27339708 · DOI · Paper page
  4. [4]Mantovani A Marchesi F Malesci A Laghi L Allavena P Tumour-associated macrophages as treatment targets in oncology Nat. Rev. Clin. Oncol. 2017 14 399 416 10.1038/nrclinonc.2016.217 28117416 PMC5480600 · DOI
  5. [5]Cassetta L Pollard JW Targeting macrophages: therapeutic approaches in cancer Nat. Rev. Drug Discov. 2018 17 887 904 10.1038/nrd.2018.169 30361552 · DOI
  6. [6]DeNardo DG Ruffell B Macrophages as regulators of tumour immunity and immunotherapy Nat. Rev. Immunol. 2019 19 369 382 10.1038/s41577-019-0127-6 30718830 PMC7339861 · DOI
  7. [7]Locati M Curtale G Mantovani A Diversity, mechanisms, and significance of macrophage plasticity Annu. Rev. Pathol. 2020 15 123 147 10.1146/annurev-pathmechdis-012418-012718 31530089 PMC7176483 · DOI · Paper page
  8. [8]Jahchan NS Tuning the tumor myeloid microenvironment to fight cancer Front. Immunol. 2019 10 1611 10.3389/fimmu.2019.01611 31402908 PMC6673698 · DOI
  9. [9]Coussens LM Zitvogel L Palucka AK Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013 339 286 291 10.1126/science.1232227 23329041 PMC3591506 · DOI
  10. [10]Cassetta L Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets Cancer Cell 2019 35 588 602 10.1016/j.ccell.2019.02.009 30930117 PMC6472943 · DOI
  11. [11]Murray PJ Macrophage activation and polarization: nomenclature and experimental guidelines Immunity 2014 41 14 20 10.1016/j.immuni.2014.06.008 25035950 PMC4123412 · DOI · Paper page
  12. [12]Kryczek I B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma J. Exp. Med. 2006 203 871 881 10.1084/jem.20050930 16606666 PMC2118300 · DOI · Paper page
  13. [13]Kim IS Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms Nat. Cell Biol. 2019 21 1113 1126 10.1038/s41556-019-0373-7 31451770 PMC6726554 · DOI
  14. [14]Klichinsky M Human chimeric antigen receptor macrophages for cancer immunotherapy Nat. Biotechnol. 2020 38 947 953 10.1038/s41587-020-0462-y 32361713 PMC7883632 · DOI · Paper page
  15. [15]Advani R CD47 Blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma N. Engl. J. Med. 2018 379 1711 1721 10.1056/NEJMoa1807315 30380386 PMC8058634 · DOI
  16. [16]Siu LL First-in-class anti-immunoglobulin-like transcript 4 myeloid-specific antibody MK-4830 abrogates a PD-1 resistance mechanism in patients with advanced solid tumors Clin. Cancer Res. 2022 28 57 70 10.1158/1078-0432.CCR-21-2160 34598945 PMC9401547 · DOI
  17. [17]Virtakoivu R Systemic blockade of clever-1 elicits lymphocyte activation alongside checkpoint molecule downregulation in patients with solid tumors: results from a phase I/II clinical trial Clin. Cancer Res. 2021 27 4205 4220 10.1158/1078-0432.CCR-20-4862 34078651 PMC9401456 · DOI
  18. [18]Bottazzi B Regulation of the macrophage content of neoplasms by chemoattractants Science 1983 220 210 212 10.1126/science.6828888 6828888 · DOI
  19. [19]Bain CC Long-lived self-renewing bone marrow-derived macrophages displace embryo-derived cells to inhabit adult serous cavities Nat. Commun. 2016 7 ncomms11852 10.1038/ncomms11852 27292029 PMC4910019 · DOI · Paper page
  20. [20]Ginhoux F Guilliams M Tissue-resident macrophage ontogeny and homeostasis Immunity 2016 44 439 449 10.1016/j.immuni.2016.02.024 26982352 · DOI · Paper page
  21. [21]Zhu Y Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression Immunity 2017 47 323 338 10.1016/j.immuni.2017.07.014 28813661 PMC5578409 · DOI
  22. [22]Etzerodt A Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer J. Exp. Med. 2020 217 e20191869 10.1084/jem.20191869 31951251 PMC7144521 · DOI
  23. [23]Blériot C Chakarov S Ginhoux F Determinants of resident tissue macrophage identity and function Immunity 2020 52 957 970 10.1016/j.immuni.2020.05.014 32553181 · DOI · Paper page
  24. [24]Gutmann DH Kettenmann H Microglia/brain macrophages as central drivers of brain tumor pathobiology Neuron 2019 104 442 449 10.1016/j.neuron.2019.08.028 31697921 PMC7288606 · DOI
  25. [25]Müller A Brandenburg S Turkowski K Müller S Vajkoczy P Resident microglia, and not peripheral macrophages, are the main source of brain tumor mononuclear cells Int. J. Cancer 2015 137 278 288 10.1002/ijc.29379 25477239 · DOI
  26. [26]Dumas AA Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment EMBO J. 2020 39 e103790 10.15252/embj.2019103790 32567735 PMC7396846 · DOI
  27. [27]Gangoso E Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion Cell 2021 184 2454 2470 10.1016/j.cell.2021.03.023 33857425 PMC8099351 · DOI
  28. [28]Casanova-Acebes M Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells Nature 2021 595 578 584 10.1038/s41586-021-03651-8 34135508 PMC8923521 · DOI
  29. [29]Pombo Antunes AR Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization Nat. Neurosci. 2021 24 595 610 10.1038/s41593-020-00789-y 33782623 · DOI · Paper page
  30. [30]Martinez-Usatorre A Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models Sci. Transl Med. 2021 13 eabd1616 10.1126/scitranslmed.abd1616 34380768 PMC7612153 · DOI
  31. [31]Singhal S Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer Sci. Transl Med. 2019 11 eaat1500 10.1126/scitranslmed.aat1500 30760579 PMC6800123 · DOI
  32. [32]Biswas SK Mantovani A Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm Nat. Immunol. 2010 11 889 896 10.1038/ni.1937 20856220 · DOI · Paper page
  33. [33]Martinez FO Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences Blood 2013 121 e57 e69 10.1182/blood-2012-06-436212 23293084 · DOI
  34. [34]Leader AM Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification Cancer Cell 2021 39 1594 1609 10.1016/j.ccell.2021.10.009 34767762 PMC8728963 · DOI
  35. [35]Li H The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1 Cancer Cell 2022 40 36 52 10.1016/j.ccell.2021.11.002 34822775 PMC8779329 · DOI
  36. [36]Pushalkar S The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression Cancer Discov. 2018 8 403 416 10.1158/2159-8290.CD-17-1134 29567829 PMC6225783 · DOI · Paper page
  37. [37]Dzutsev A Microbes and cancer Annu. Rev. Immunol. 2017 35 199 228 10.1146/annurev-immunol-051116-052133 28142322 · DOI · Paper page
  38. [38]Zhang Q Gut microbiome directs hepatocytes to recruit MDSCs and promote cholangiocarcinoma Cancer Discov. 2021 11 1248 1267 10.1158/2159-8290.CD-20-0304 33323397 PMC8102309 · DOI
  39. [39]Roy S Trinchieri G Microbiota: a key orchestrator of cancer therapy Nat. Rev. Cancer 2017 17 271 285 10.1038/nrc.2017.13 28303904 · DOI · Paper page
  40. [40]Movahedi K Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes Cancer Res. 2010 70 5728 5739 10.1158/0008-5472.CAN-09-4672 20570887 · DOI
  41. [41]Lavin Y Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses Cell 2017 169 750 765 10.1016/j.cell.2017.04.014 28475900 PMC5737939 · DOI · Paper page
  42. [42]Lambrechts D Phenotype molding of stromal cells in the lung tumor microenvironment Nat. Med. 2018 24 1277 1289 10.1038/s41591-018-0096-5 29988129 · DOI · Paper page
  43. [43]Zilionis R Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species Immunity 2019 50 1317 1334 10.1016/j.immuni.2019.03.009 30979687 PMC6620049 · DOI
  44. [44]Klemm F Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells Cell 2020 181 1643 1660 10.1016/j.cell.2020.05.007 32470396 PMC8558904 · DOI
  45. [45]Friebel E Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes Cell 2020 181 1626 1642 10.1016/j.cell.2020.04.055 32470397 · DOI
  46. [46]Azizi E Single-cell map of diverse immune phenotypes in the breast tumor microenvironment Cell 2018 174 1293 1308 10.1016/j.cell.2018.05.060 29961579 PMC6348010 · DOI · Paper page
  47. [47]Puram SV Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer Cell 2017 171 1611 1624 10.1016/j.cell.2017.10.044 29198524 PMC5878932 · DOI · Paper page
  48. [48]Tirosh I Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq Science 2016 352 189 196 10.1126/science.aad0501 27124452 PMC4944528 · DOI · Paper page
  49. [49]Chevrier S An immune atlas of clear cell renal cell carcinoma Cell 2017 169 736 749 10.1016/j.cell.2017.04.016 28475899 PMC5422211 · DOI
  50. [50]Donadon M Macrophage morphology correlates with single-cell diversity and prognosis in colorectal liver metastasis J. Exp. Med. 2020 217 e20191847 10.1084/jem.20191847 32785653 PMC7596819 · DOI
  51. [51]Braun DA Progressive immune dysfunction with advancing disease stage in renal cell carcinoma Cancer Cell 2021 39 632 648 10.1016/j.ccell.2021.02.013 33711273 PMC8138872 · DOI
  52. [52]Zhang L Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer Cell 2020 181 442 459 10.1016/j.cell.2020.03.048 32302573 · DOI
  53. [53]Pelka K Spatially organized multicellular immune hubs in human colorectal cancer Cell 2021 184 4734 4752 10.1016/j.cell.2021.08.003 34450029 PMC8772395 · DOI
  54. [54]Cortese N Carriero R Laghi L Mantovani A Marchesi F Prognostic significance of tumor-associated macrophages: past, present and future Semin. Immunol. 2020 48 101408 10.1016/j.smim.2020.101408 32943279 · DOI
  55. [55]Forssell J High macrophage infiltration along the tumor front correlates with improved survival in colon cancer Clin. Cancer Res. 2007 13 1472 1479 10.1158/1078-0432.CCR-06-2073 17332291 · DOI
  56. [56]Malesci A Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer Oncoimmunology 2017 6 e1342918 10.1080/2162402X.2017.1342918 29209561 PMC5706531 · DOI · Paper page
  57. [58]Ruffell B Coussens LM Macrophages and therapeutic resistance in cancer Cancer Cell 2015 27 462 472 10.1016/j.ccell.2015.02.015 25858805 PMC4400235 · DOI · Paper page
  58. [59]Galluzzi L Humeau J Buqué A Zitvogel L Kroemer G Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors Nat. Rev. Clin. Oncol. 2020 17 725 741 10.1038/s41571-020-0413-z 32760014 · DOI · Paper page
  59. [60]Germano G Role of macrophage targeting in the antitumor activity of trabectedin Cancer Cell 2013 23 249 262 10.1016/j.ccr.2013.01.008 23410977 · DOI
  60. [61]Di Caro G Dual prognostic significance of tumour-associated macrophages in human pancreatic adenocarcinoma treated or untreated with chemotherapy Gut 2016 65 1710 1720 10.1136/gutjnl-2015-309193 26156960 · DOI
  61. [62]Heath O Chemotherapy induces tumor-associated macrophages that aid adaptive immune responses in ovarian cancer Cancer Immunol. Res. 2021 9 665 681 10.1158/2326-6066.CIR-20-0968 33839687 PMC7611478 · DOI
  62. [63]Iida N Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment Science 2013 342 967 970 10.1126/science.1240527 24264989 PMC6709532 · DOI · Paper page
  63. [64]Shiao SL Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy Cancer Cell 2021 39 1202 1213.e6 10.1016/j.ccell.2021.07.002 34329585 PMC8830498 · DOI
  64. [65]Singh S FDA approval summary: lurbinectedin for the treatment of metastatic small cell lung cancer Clin. Cancer Res. 2021 27 2378 2382 10.1158/1078-0432.CCR-20-3901 33288660 PMC9532454 · DOI
  65. [66]Shaked Y The pro-tumorigenic host response to cancer therapies Nat. Rev. Cancer 2019 19 667 685 10.1038/s41568-019-0209-6 31645711 · DOI
  66. [67]Li J PI3Kγ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response Proc. Natl Acad. Sci. USA 2021 118 e2009290118 10.1073/pnas.2009290118 33846242 PMC8072253 · DOI
  67. [68]Paulus P Stanley ER Schafer R Abraham D Aharinejad S Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts Cancer Res. 2006 66 4349 4356 10.1158/0008-5472.CAN-05-3523 16618760 · DOI
  68. [69]DeNardo DG Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy Cancer Discov. 2011 1 54 67 10.1158/2159-8274.CD-10-0028 22039576 PMC3203524 · DOI · Paper page
  69. [70]Mitchem JB Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses Cancer Res. 2013 73 1128 1141 10.1158/0008-5472.CAN-12-2731 23221383 PMC3563931 · DOI
  70. [71]Salvagno C Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response Nat. Cell Biol. 2019 21 511 521 10.1038/s41556-019-0298-1 30886344 PMC6451630 · DOI
  71. [72]Gomez-Roca CA Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages Ann. Oncol. 2019 30 1381 1392 10.1093/annonc/mdz163 31114846 PMC8887589 · DOI
  72. [73]Gül N van Egmond M Antibody-dependent phagocytosis of tumor cells by macrophages: a potent effector mechanism of monoclonal antibody therapy of cancer Cancer Res. 2015 75 5008 5013 10.1158/0008-5472.CAN-15-1330 26573795 · DOI
  73. [74]DiLillo DJ Ravetch JV Fc-receptor interactions regulate both cytotoxic and immunomodulatory therapeutic antibody effector functions Cancer Immunol. Res. 2015 3 704 713 10.1158/2326-6066.CIR-15-0120 26138698 · DOI
  74. [75]Uchida J The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy J. Exp. Med. 2004 199 1659 1669 10.1084/jem.20040119 15210744 PMC2212805 · DOI
  75. [76]Weng WK Levy R Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma J. Clin. Oncol. 2003 21 3940 3947 10.1200/JCO.2003.05.013 12975461 · DOI
  76. [77]Musolino A Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer J. Clin. Oncol. 2008 26 1789 1796 10.1200/JCO.2007.14.8957 18347005 · DOI · Paper page
  77. [79]Lapenna A De Palma M Lewis CE Perivascular macrophages in health and disease Nat. Rev. Immunol. 2018 18 689 702 10.1038/s41577-018-0056-9 30127389 · DOI
  78. [80]Greenberg JI A role for VEGF as a negative regulator of pericyte function and vessel maturation Nature 2008 456 809 813 10.1038/nature07424 18997771 PMC2605188 · DOI
  79. [81]Peterson TE Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages Proc. Natl Acad. Sci. USA 2016 113 4470 4475 10.1073/pnas.1525349113 27044097 PMC4843449 · DOI · Paper page
  80. [83]Stender JD Structural and molecular mechanisms of cytokine-mediated endocrine resistance in human breast cancer cells Mol. Cell 2017 65 1122 1135 10.1016/j.molcel.2017.02.008 28306507 PMC5546241 · DOI
  81. [84]Siersbæk R IL6/STAT3 signaling hijacks estrogen receptor α enhancers to drive breast cancer metastasis Cancer Cell 2020 38 412 423 10.1016/j.ccell.2020.06.007 32679107 PMC7116707 · DOI
  82. [85]Cioni B Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion Nat. Commun. 2020 11 4498 10.1038/s41467-020-18313-y 32908142 PMC7481219 · DOI
  83. [86]Calcinotto A IL-23 secreted by myeloid cells drives castration-resistant prostate cancer Nature 2018 559 363 369 10.1038/s41586-018-0266-0 29950727 PMC6461206 · DOI · Paper page
  84. [87]Formenti SC Demaria S Systemic effects of local radiotherapy Lancet Oncol. 2009 10 718 726 10.1016/S1470-2045(09)70082-8 19573801 PMC2782943 · DOI
  85. [88]Sharma P Hu-Lieskovan S Wargo JA Ribas A Primary, adaptive, and acquired resistance to cancer immunotherapy Cell 2017 168 707 723 10.1016/j.cell.2017.01.017 28187290 PMC5391692 · DOI · Paper page
  86. [89]Kuang DM Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1 J. Exp. Med. 2009 206 1327 1337 10.1084/jem.20082173 19451266 PMC2715058 · DOI
  87. [90]Bloch O Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages Clin. Cancer Res. 2013 19 3165 3175 10.1158/1078-0432.CCR-12-3314 23613317 PMC3742575 · DOI
  88. [92]Havel JJ Chowell D Chan TA The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy Nat. Rev. Cancer 2019 19 133 150 10.1038/s41568-019-0116-x 30755690 PMC6705396 · DOI · Paper page
  89. [93]Tang H PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression J. Clin. Invest. 2018 128 580 588 10.1172/JCI96061 29337303 PMC5785245 · DOI
  90. [94]Gordon SR PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity Nature 2017 545 495 499 10.1038/nature22396 28514441 PMC5931375 · DOI · Paper page
  91. [95]Strauss L Targeted deletion of PD-1 in myeloid cells induces antitumor immunity Sci. Immunol. 2020 5 eaay1863 10.1126/sciimmunol.aay1863 31901074 PMC7183328 · DOI · Paper page
  92. [96]Laba S Mallett G Amarnath S The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells Semin. Cancer Biol. 2021 10.1016/j.semcancer.2021.05.022 34048897 · DOI
  93. [97]Wang L VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses J. Exp. Med. 2011 208 577 592 10.1084/jem.20100619 21383057 PMC3058578 · DOI
  94. [98]Johnston RJ VISTA is an acidic pH-selective ligand for PSGL-1 Nature 2019 574 565 570 10.1038/s41586-019-1674-5 31645726 · DOI
  95. [99]Rogers BM VISTA is an activating receptor in human monocytes J. Exp. Med. 2021 218 e20201601 10.1084/jem.20201601 34106206 PMC8193568 · DOI
  96. [100]Yu J Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination Nat. Med. 2021 27 152 164 10.1038/s41591-020-1131-x 33398162 PMC8095049 · DOI
  97. [101]Chow A Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity Cancer Cell 2021 39 973 988 10.1016/j.ccell.2021.05.006 34115989 PMC9115604 · DOI
  98. [102]Krishna C Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy Cancer Cell 2021 39 662 677 10.1016/j.ccell.2021.03.007 33861994 PMC8268947 · DOI
  99. [103]Koh MY Sayegh N Agarwal N Seeing the forest for the trees-single-cell atlases link CD8 Cancer Cell 2021 39 594 596 10.1016/j.ccell.2021.03.008 33861995 · DOI · Paper page
  100. [106]Fridlender ZG CCL2 blockade augments cancer immunotherapy Cancer Res. 2010 70 109 118 10.1158/0008-5472.CAN-09-2326 20028856 PMC2821565 · DOI
  101. [107]Zhu Y CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models Cancer Res. 2014 74 5057 5069 10.1158/0008-5472.CAN-13-3723 25082815 PMC4182950 · DOI · Paper page
  102. [108]Peranzoni E Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment Proc. Natl Acad. Sci. USA 2018 115 E4041 E4050 10.1073/pnas.1720948115 29632196 PMC5924916 · DOI
  103. [109]Neubert NJ T cell-induced CSF1 promotes melanoma resistance to PD1 blockade Sci. Transl Med. 2018 10 eaan3311 10.1126/scitranslmed.aan3311 29643229 PMC5957531 · DOI · Paper page
  104. [110]Beltraminelli T De Palma M Biology and therapeutic targeting of tumour-associated macrophages J. Pathol. 2020 250 573 592 10.1002/path.5403 32086811 · DOI
  105. [111]Argyle D Kitamura T Targeting macrophage-recruiting chemokines as a novel therapeutic strategy to prevent the progression of solid tumors Front. Immunol. 2018 9 2629 10.3389/fimmu.2018.02629 30483271 PMC6243037 · DOI
  106. [113]Ries CH Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy Cancer Cell 2014 25 846 859 10.1016/j.ccr.2014.05.016 24898549 · DOI · Paper page
  107. [114]Pfirschke C Macrophage-targeted therapy unlocks antitumoral cross-talk between IFNγ-secreting lymphocytes and IL12-producing dendritic cells Cancer Immunol. Res. 2022 10 40 55 10.1158/2326-6066.CIR-21-0326 34795032 PMC10132467 · DOI
  108. [115]Cassier PA Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour Eur. J. Cancer 2020 141 162 170 10.1016/j.ejca.2020.09.038 33161240 · DOI
  109. [116]Bissinger S Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition Sci. Transl Med. 2021 13 eabd4550 10.1126/scitranslmed.abd4550 34135110 · DOI
  110. [117]Rodriguez-Garcia A CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy Nat. Commun. 2021 12 877 10.1038/s41467-021-20893-2 33563975 PMC7873057 · DOI
  111. [118]Etzerodt A Specific targeting of CD163 mobilizes inflammatory monocytes and promotes T cell-mediated tumor regression J. Exp. Med. 2019 216 2394 2411 10.1084/jem.20182124 31375534 PMC6781002 · DOI
  112. [119]Reis ES Mastellos DC Ricklin D Mantovani A Lambris JD Complement in cancer: untangling an intricate relationship Nat. Rev. Immunol. 2018 18 5 18 10.1038/nri.2017.97 28920587 PMC5816344 · DOI
  113. [120]Pio R Ajona D Ortiz-Espinosa S Mantovani A Lambris JD Complementing the cancer-immunity cycle Front. Immunol. 2019 10 774 10.3389/fimmu.2019.00774 31031765 PMC6473060 · DOI
  114. [121]Markiewski MM Modulation of the antitumor immune response by complement Nat. Immunol. 2008 9 1225 1235 10.1038/ni.1655 18820683 PMC2678913 · DOI
  115. [122]Magrini E Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression Nat. Cancer 2021 2 218 232 10.1038/s43018-021-00173-0 34505065 PMC8425276 · DOI
  116. [123]Medler TR Complement C5a fosters squamous carcinogenesis and limits T cell response to chemotherapy Cancer Cell 2018 34 561 578 10.1016/j.ccell.2018.09.003 30300579 PMC6246036 · DOI
  117. [124]Laskowski J Complement factor H-deficient mice develop spontaneous hepatic tumors J. Clin. Invest. 2020 130 4039 4054 32369457 PMC7410061
  118. [125]Daugan MV Intracellular factor H drives tumor progression independently of the complement cascade Cancer Immunol. Res 2021 9 909 925 10.1158/2326-6066.CIR-20-0787 34039652 · DOI
  119. [126]Roumenina LT Daugan MV Petitprez F Sautès-Fridman C Fridman WH Context-dependent roles of complement in cancer Nat. Rev. Cancer 2019 19 698 715 10.1038/s41568-019-0210-0 31666715 · DOI
  120. [127]Roumenina LT Tumor cells hijack macrophage-produced complement C1q to promote tumor growth Cancer Immunol. Res. 2019 7 1091 1105 10.1158/2326-6066.CIR-18-0891 31164356 · DOI
  121. [128]Bonavita E PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer Cell 2015 160 700 714 10.1016/j.cell.2015.01.004 25679762 · DOI
  122. [129]Rubino M Epigenetic regulation of the extrinsic oncosuppressor PTX3 gene in inflammation and cancer Oncoimmunology 2017 6 e1333215 10.1080/2162402X.2017.1333215 28811977 PMC5543905 · DOI
  123. [130]Vadrevu SK Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche Cancer Res. 2014 74 3454 3465 10.1158/0008-5472.CAN-14-0157 24786787 · DOI
  124. [131]Ajona D A combined PD-1/C5a blockade synergistically protects against lung cancer growth and metastasis Cancer Discov. 2017 7 694 703 10.1158/2159-8290.CD-16-1184 28288993 · DOI
  125. [132]Mantovani A Dinarello CA Molgora M Garlanda C Interleukin-1 and related cytokines in the regulation of inflammation and immunity Immunity 2019 50 778 795 10.1016/j.immuni.2019.03.012 30995499 PMC7174020 · DOI · Paper page
  126. [133]Ridker PM Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial Lancet 2017 390 1833 1842 10.1016/S0140-6736(17)32247-X 28855077 · DOI · Paper page
  127. [134]Garlanda C Mantovani A Interleukin-1 in tumor progression, therapy, and prevention Cancer Cell 2021 39 1023 1027 10.1016/j.ccell.2021.04.011 33989512 · DOI
  128. [135]Kaplanov I Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation Proc. Natl Acad. Sci. USA 2019 116 1361 1369 10.1073/pnas.1812266115 30545915 PMC6347724 · DOI
  129. [136]Aggen DH Blocking IL1 beta promotes tumor regression and remodeling of the myeloid compartment in a renal cell carcinoma model: multidimensional analyses Clin. Cancer Res. 2021 27 608 621 10.1158/1078-0432.CCR-20-1610 33148676 PMC7980495 · DOI
  130. [137]Wong CC Inhibition of IL1β by canakinumab may be effective against diverse molecular subtypes of lung cancer: an exploratory analysis of the CANTOS trial Cancer Res. 2020 80 5597 5605 10.1158/0008-5472.CAN-19-3176 33023946 · DOI
  131. [138]Tengesdal IW Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion Proc. Natl Acad. Sci. USA 2021 118 e2000915118 10.1073/pnas.2000915118 33649199 PMC7958415 · DOI
  132. [139]Zhang F Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers Nat. Commun. 2019 10 3974 10.1038/s41467-019-11911-5 31481662 PMC6722139 · DOI
  133. [140]Curtale G Rubino M Locati M MicroRNAs as molecular switches in macrophage activation Front. Immunol. 2019 10 799 10.3389/fimmu.2019.00799 31057539 PMC6478758 · DOI
  134. [141]Zang X Targeted delivery of miRNA 155 to tumor associated macrophages for tumor immunotherapy Mol. Pharm. 2019 16 1714 1722 10.1021/acs.molpharmaceut.9b00065 30860846 · DOI
  135. [142]Baer C Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity Nat. Cell Biol. 2016 18 790 802 10.1038/ncb3371 27295554 · DOI · Paper page
  136. [143]Lopez-Yrigoyen M Cassetta L Pollard JW Macrophage targeting in cancer Ann. NY Acad. Sci. 2021 1499 18 41 10.1111/nyas.14377 32445205 · DOI
  137. [144]Allavena P Anfray C Ummarino A Andón FT Therapeutic manipulation of tumor-associated macrophages: facts and hopes from a clinical and translational perspective Clin. Cancer Res. 2021 27 3291 3297 10.1158/1078-0432.CCR-20-1679 33531428 · DOI
  138. [145]Beatty GL A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma Clin. Cancer Res. 2013 19 6286 6295 10.1158/1078-0432.CCR-13-1320 23983255 PMC3834036 · DOI
  139. [146]Huffman AP Lin JH Kim SI Byrne KT Vonderheide RH CCL5 mediates CD40-driven CD4+ T cell tumor infiltration and immunity JCI Insight 2020 5 e137263 10.1172/jci.insight.137263 PMC7259512 32324594 · DOI
  140. [147]Hoves S Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity J. Exp. Med. 2018 215 859 876 10.1084/jem.20171440 29436396 PMC5839760 · DOI
  141. [149]Ji N Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial Oncoimmunology 2019 8 1614857 10.1080/2162402X.2019.1614857 31413921 PMC6682354 · DOI
  142. [150]McWhirter SM Jefferies CA Nucleic acid sensors as therapeutic targets for human disease Immunity 2020 53 78 97 10.1016/j.immuni.2020.04.004 32668230 · DOI
  143. [152]Pettenati C Ingersoll MA Mechanisms of BCG immunotherapy and its outlook for bladder cancer Nat. Rev. Urol. 2018 15 615 625 10.1038/s41585-018-0055-4 29991725 · DOI
  144. [153]Sun L Activating a collaborative innate-adaptive immune response to control metastasis Cancer Cell 2021 39 1361 1374 10.1016/j.ccell.2021.08.005 34478639 PMC8981964 · DOI
  145. [154]Anfray C Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity J. Immunother. Cancer 2021 9 e002408 10.1136/jitc-2021-002408 34531246 PMC8449972 · DOI
  146. [156]Márquez-Rodas I Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors Sci. Transl Med. 2020 12 eabb0391 10.1126/scitranslmed.abb0391 33055241 · DOI
  147. [157]Kyi C Therapeutic immune modulation against solid cancers with intratumoral poly-ICLC: a pilot trial Clin. Cancer Res. 2018 24 4937 4948 10.1158/1078-0432.CCR-17-1866 29950349 PMC6191332 · DOI
  148. [159]Irvine DJ Dane EL Enhancing cancer immunotherapy with nanomedicine Nat. Rev. Immunol. 2020 20 321 334 10.1038/s41577-019-0269-6 32005979 PMC7536618 · DOI
  149. [160]Lu R Formulation and preclinical evaluation of a toll-like receptor 7/8 agonist as an anti-tumoral immunomodulator J. Control. Rel. 2019 306 165 176 10.1016/j.jconrel.2019.06.003 PMC6679596 31173789 · DOI
  150. [161]Ribas A Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma Cancer Discov. 2021 11 2998 3007 10.1158/2159-8290.CD-21-0425 34326162 PMC8799774 · DOI · Paper page
  151. [162]Ackerman SE Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity Nat. Cancer 2021 2 18 33 10.1038/s43018-020-00136-x 35121890 PMC9012298 · DOI
  152. [163]Chow LQM Phase Ib trial of the toll-like receptor 8 agonist, motolimod (VTX-2337), combined with cetuximab in patients with recurrent or metastatic SCCHN Clin. Cancer Res. 2017 23 2442 2450 10.1158/1078-0432.CCR-16-1934 27810904 · DOI
  153. [164]Ferris RL Effect of adding motolimod to standard combination chemotherapy and cetuximab treatment of patients with squamous cell carcinoma of the head and neck: the active8 randomized clinical trial JAMA Oncol. 2018 4 1583 1588 10.1001/jamaoncol.2018.1888 29931076 PMC6248084 · DOI
  154. [165]Frank MJ In situ vaccination with a TLR9 agonist and local low-dose radiation induces systemic responses in untreated indolent lymphoma Cancer Discov. 2018 8 1258 1269 10.1158/2159-8290.CD-18-0743 30154192 PMC6171524 · DOI
  155. [166]Karapetyan L Luke JJ Davar D Toll-like receptor 9 agonists in cancer OncoTargets Ther. 2020 13 10039 10060 10.2147/OTT.S247050 PMC7553670 33116588 · DOI
  156. [167]Li JK Balic JJ Yu L Jenkins B TLR agonists as adjuvants for cancer vaccines Adv. Exp. Med. Biol. 2017 1024 195 212 10.1007/978-981-10-5987-2_9 28921471 · DOI
  157. [168]Vermaelen K Vaccine strategies to improve anti-cancer cellular immune responses Front. Immunol. 2019 10 8 10.3389/fimmu.2019.00008 30723469 PMC6349827 · DOI
  158. [169]Kalbasi A Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma Sci. Transl Med. 2020 12 eabb0152 10.1126/scitranslmed.abb0152 33055240 PMC8053376 · DOI
  159. [170]Smith M Trial watch: toll-like receptor agonists in cancer immunotherapy Oncoimmunology 2018 7 e1526250 10.1080/2162402X.2018.1526250 30524908 PMC6279325 · DOI
  160. [171]Ishikawa H Barber GN STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling Nature 2008 455 674 678 10.1038/nature07317 18724357 PMC2804933 · DOI · Paper page
  161. [172]Vanpouille-Box C Hoffmann JA Galluzzi L Pharmacological modulation of nucleic acid sensors- therapeutic potential and persisting obstacles Nat. Rev. Drug Discov. 2019 18 845 867 10.1038/s41573-019-0043-2 31554927 · DOI · Paper page
  162. [174]Zhou S Kestell P Baguley BC Paxton JW 5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy Invest. New Drugs 2002 20 281 295 10.1023/A:1016215015530 12201491 · DOI
  163. [175]Motedayen Aval L Pease JE Sharma R Pinato DJ Challenges and opportunities in the clinical development of STING agonists for cancer immunotherapy J. Clin. Med. 2020 9 3323 10.3390/jcm9103323 PMC7602874 33081170 · DOI
  164. [176]Zou SS Intrinsic strategies for the evasion of cGAS-STING signaling-mediated immune surveillance in human cancer: how therapy can overcome them Pharmacol. Res. 2021 166 105514 10.1016/j.phrs.2021.105514 33631336 · DOI
  165. [178]Lam KC Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment Cell 2021 184 5338 5356 10.1016/j.cell.2021.09.019 34624222 PMC8650838 · DOI · Paper page
  166. [179]Barkal AA CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy Nature 2019 572 392 396 10.1038/s41586-019-1456-0 31367043 PMC6697206 · DOI
  167. [180]Mantovani A Longo DL Macrophage checkpoint blockade in cancer - back to the future N. Engl. J. Med. 2018 379 1777 1779 10.1056/NEJMe1811699 30380398 · DOI
  168. [181]Feng M Phagocytosis checkpoints as new targets for cancer immunotherapy Nat. Rev. Cancer 2019 19 568 586 10.1038/s41568-019-0183-z 31462760 PMC7002027 · DOI
  169. [183]Jaiswal S CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis Cell 2009 138 271 285 10.1016/j.cell.2009.05.046 19632178 PMC2775564 · DOI
  170. [184]Gholamin S Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors Sci. Transl Med. 2017 9 eaaf2968 10.1126/scitranslmed.aaf2968 28298418 · DOI
  171. [185]Tseng D Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response Proc. Natl Acad. Sci. USA 2013 110 11103 11108 10.1073/pnas.1305569110 23690610 PMC3703977 · DOI
  172. [186]Ring NG Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity Proc. Natl Acad. Sci. USA 2017 114 E10578 E10585 10.1073/pnas.1710877114 29158380 PMC5724266 · DOI
  173. [187]Zhang M Anti-CD47 treatment stimulates phagocytosis of glioblastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages in vivo PLoS ONE 2016 11 e0153550 10.1371/journal.pone.0153550 27092773 PMC4836698 · DOI
  174. [188]Weiskopf K CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer J. Clin. Invest. 2016 126 2610 2620 10.1172/JCI81603 27294525 PMC4922696 · DOI
  175. [189]Upton R Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance Proc. Natl Acad. Sci. USA 2021 118 e2026849118 10.1073/pnas.2026849118 34257155 PMC8307693 · DOI
  176. [190]van Bommel PE CD20-selective inhibition of CD47-SIRPα “don’t eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab Oncoimmunology 2018 7 e1386361 10.1080/2162402X.2017.1386361 29308308 PMC5749665 · DOI
  177. [191]Wang Y Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity Cancer Immunol. Immunother. 2021 70 365 376 10.1007/s00262-020-02679-5 32761423 PMC10991320 · DOI
  178. [192]Hendriks MAJM Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα “don’t eat me” immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation Oncoimmunology 2020 9 1824323 10.1080/2162402X.2020.1824323 33299654 PMC7714490 · DOI
  179. [193]Tian L Targeting Fc receptor-mediated effects and the “don’t eat me” signal with an oncolytic virus expressing an anti-CD47 antibody to treat metastatic ovarian cancer Clin. Cancer Res. 2022 28 201 214 10.1158/1078-0432.CCR-21-1248 34645647 PMC8963132 · DOI
  180. [194]Jing W Breast cancer cells promote CD169+ macrophage-associated immunosuppression through JAK2-mediated PD-L1 upregulation on macrophages Int. Immunopharmacol. 2020 78 106012 10.1016/j.intimp.2019.106012 31865052 · DOI
  181. [195]Ibarlucea-Benitez I Weitzenfeld P Smith P Ravetch JV Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity Proc. Natl Acad. Sci. USA 2021 118 e2107424118 10.1073/pnas.2107424118 34155121 PMC8256000 · DOI
  182. [196]Festenstein H Garrido F MHC antigens and malignancy Nature 1986 322 502 503 10.1038/322502a0 3461283 · DOI
  183. [197]Barkal AA Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy Nat. Immunol. 2018 19 76 84 10.1038/s41590-017-0004-z 29180808 PMC5832354 · DOI
  184. [198]Chen HM Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity J. Clin. Invest. 2018 128 5647 5662 10.1172/JCI97570 30352428 PMC6264729 · DOI
  185. [199]Sharma N Atolagbe OT Ge Z Allison JP LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy J. Exp. Med. 2021 218 e20201811 10.1084/jem.20201811 33974041 PMC8117208 · DOI
  186. [200]Jensen TO Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma J. Clin. Oncol. 2009 27 3330 3337 10.1200/JCO.2008.19.9919 19528371 · DOI
  187. [201]Lau SK Chu PG Weiss LM CD163: a specific marker of macrophages in paraffin-embedded tissue samples Am. J. Clin. Pathol. 2004 122 794 801 10.1309/QHD6YFN81KQXUUH6 15491976 · DOI
  188. [202]Allavena P Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages Clin. Dev. Immunol. 2010 2010 547179 10.1155/2010/547179 21331365 PMC3038419 · DOI
  189. [203]Chieppa M Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program J. Immunol. 2003 171 4552 4560 10.4049/jimmunol.171.9.4552 14568928 · DOI
  190. [204]Heinsbroek SE miR-511-3p, embedded in the macrophage mannose receptor gene, contributes to intestinal inflammation Mucosal Immunol. 2016 9 960 973 10.1038/mi.2015.113 26530135 · DOI
  191. [205]Rahabi M Divergent roles for macrophage C-type lectin receptors, dectin-1 and mannose receptors, in the intestinal inflammatory response Cell Rep. 2020 30 4386 4398 10.1016/j.celrep.2020.03.018 32234475 · DOI
  192. [206]Jaynes JM Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses Sci. Transl Med. 2020 12 eaax6337 10.1126/scitranslmed.aax6337 32051227 PMC7832040 · DOI
  193. [207]Georgoudaki AM Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis Cell Rep. 2016 15 2000 2011 10.1016/j.celrep.2016.04.084 27210762 · DOI · Paper page
  194. [208]La Fleur L Targeting MARCO and IL37R on immunosuppressive macrophages in lung cancer blocks regulatory T cells and supports cytotoxic lymphocyte function Cancer Res. 2021 81 956 967 10.1158/0008-5472.CAN-20-1885 33293426 · DOI
  195. [209]Molgora M IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity Nature 2017 551 110 114 10.1038/nature24293 29072292 PMC5768243 · DOI
  196. [210]Eisinger S Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells Proc. Natl Acad. Sci. USA 2020 117 32005 32016 10.1073/pnas.2015343117 33229588 PMC7750482 · DOI
  197. [211]Sa JK Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma Genome Biol. 2020 21 216 10.1186/s13059-020-02140-x 32847614 PMC7448990 · DOI
  198. [212]Palani S Stabilin-1/CLEVER-1, a type 2 macrophage marker, is an adhesion and scavenging molecule on human placental macrophages Eur. J. Immunol. 2011 41 2052 2063 10.1002/eji.201041376 21480214 · DOI
  199. [213]Viitala M Immunotherapeutic blockade of macrophage clever-1 reactivates the CD8 Clin. Cancer Res. 2019 25 3289 3303 10.1158/1078-0432.CCR-18-3016 30755440 · DOI
  200. [215]Katzenelenbogen Y Coupled scRNA-Seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer Cell 2020 182 872 885 10.1016/j.cell.2020.06.032 32783915 · DOI · Paper page

200 of 259 shown

Cited by

Sorted by citations

Authors
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C.
Affiliations
  • Humanitas University (IT)
  • University of Milan (IT)
Corresponding author
Mantovani, Alberto
ORCID
Venue
Nature Reviews Drug Discovery
Publisher
Springer Science and Business Media LLC
Published
2022-08-16
Volume
21
Issue
11
Pages
799-820
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
DOI
10.1038/s41573-022-00520-5
PMC
PMC9380983
OpenAlex
W4291993576
Cited by
1,807
References
20
Citations by year
2026: 333 · 2025: 512 · 2024: 605 · 2023: 332 · 2022: 25
FWCI
39.13
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Queen Mary Research Online (Queen Mary University of London) (submittedVersion)
Funders
  • EuroNanoMed III
  • Ministero della Salute (RF-2019, RF-2019-12369142, “5×1000”, RF-2013-02355470)
  • Associazione Italiana per la Ricerca sul Cancro (5×1000, IG 21714, 21147,, 23465)
  • Agencia Estatal de Investigación
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
Keywords
tumour-associated macrophages, tumor microenvironment, macrophage polarization, myeloid cell recruitment, immune checkpoint blockade, chimeric antigen receptor macrophages, tumor immunosuppression, chemoresistance, metastasis, angiogenesis, extracellular matrix remodeling
MeSH terms
Antineoplastic Agents, Humans, Immunotherapy, Macrophages, Neoplasms, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review